Finally, the tissue-specific context of oncogene mutations is clearly critical in determining sensitivity to targeted therapies; notably, single-agent BRAF inhibitors or combination of BRAF and MEK inhibitors are effective inBRAF-mutant melanomas [59, 60], while they are not effective in BRAF-mutant CRCs [61, 62]. Here, MAP2K7 is linked to melanoma.